Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare Psychedelics

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Post by paulindoonon Jul 29, 2019 9:24am

249 Views

Post# 29969855

Non liking this condition

From the NR: “The dividend will be paid in kind by the distribution of shares of a subsidiary corporation (Spin-Co) holding all the issued shares of Broadway's wholly owned Montana subsidiary, Broadway Gold Corp., and the Tsumeb land package in Namibia. Spin-Co is not expected to seek a concurrent listing of these shares on any stock exchange.”
So, if not seeking a stock exchange listing, how are we shareholderable to DUMP our shares?
Stuck again!!!

Bullboard Posts

Nintendo stock hits new all-time high as excitement builds over Switch successor